Electromed is a medical devices business based in the US. Electromed shares (ELMD) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $28.81 – an increase of 13.02% over the previous week. Electromed employs 174 staff and has a trailing 12-month revenue of around $54.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $28.81 |
|---|---|
| 52-week range | $9.81 - $30.00 |
| 50-day moving average | $21.70 |
| 200-day moving average | $16.81 |
| Wall St. target price | $33.00 |
| PE ratio | 48.15 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.60 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $28.89 from 2024-11-14
| 1 week (2024-11-08) | 13.34% |
|---|---|
| 1 month (2024-10-15) | 26.16% |
| 3 months (2024-08-15) | 100.07% |
| 6 months (2024-05-15) | 65.65% |
| 1 year (2023-11-15) | 177.79% |
|---|---|
| 2 years (2022-11-15) | 184.91% |
| 3 years (2021-11-15) | 129.29% |
| 5 years (2019-11-15) | 190.35% |
Valuing Electromed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Electromed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Electromed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, Electromed shares trade at around 48x recent earnings.
Electromed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.4 million.
The EBITDA is a measure of a Electromed's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $54.7 million |
|---|---|
| Operating margin TTM | 15.74% |
| Gross profit TTM | $36.5 million |
| Return on assets TTM | 8.39% |
| Return on equity TTM | 12.53% |
| Profit margin | 9.41% |
| Book value | $5.16 |
| Market Capitalization | $242.8 million |
TTM: trailing 12 months
We're not expecting Electromed to pay a dividend over the next 12 months.
Over the last 12 months, Electromed's shares have ranged in value from as little as $9.81 up to $30. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Electromed's is 0.264. This would suggest that Electromed's shares are less volatile than average (for this exchange).
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.